免疫性智能放射治疗生物材料 (iSRB) 药理学临床前研究

Michele Moreau1,2,3, Shahinur Acter2, Lindokuhle M Ngema2,4

  • 1Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Pharmaceutics
|December 23, 2023
PubMed
概括

装有抗CD40的免疫性智能放射疗法生物材料 (iSRBs) 在健康小鼠中没有显著的毒性. 这项研究证实了iSRBs对潜在的癌症治疗开发的安全性.